Angelini Ventures co-leads Series A financing in Neumirna Therapeutics

Investment to support RNA therapeutics for epilepsy and neurological disorders

Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics.

The financing, also led by Invivo Partners, saw participation from Innovestor’s Life Science Fund and other existing investors.

The funds will support clinical development of Neumirna’s lead asset, NMT.001. This potential disease-modifying Antisense Oligonucleotide (ASO) therapy is aimed at treating drug-resistant epilepsy.

The proceeds will also expand Neumirna’s R&D capabilities and scale its pioneering drug discovery platform.

Neumirna, founded in 2020 by Dr Henrik Klitgaard, Prof. Sakari Kauppinen, and Lars Hellerung Christiansen, focuses on revolutionising treatment for neurological conditions.

By harnessing microRNAs (miRNAs), Neumirna aims to provide disease-modifying drugs for conditions like drug-resistant epilepsy and Parkinson’s disease.

Thomas Thestrup, Senior Principal at Angelini Ventures, said: “As co-lead investors, we are proud to support Neumirna in its mission to harness the potential of RNA therapies to tackle epilepsy and other complex neurological disorders.

“By leveraging microRNA-targeted drugs to address the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field. With our strong focus on brain disorders and a commitment to advancing innovative treatments for epilepsy, we are excited to collaborate with Neumirna’s management team on this journey to develop transformative solutions for patients worldwide,” he added.

Professor Janine Erler, CEO of Neumirna Therapeutics, commented: “This funding milestone is a testament to the groundbreaking potential of our RNA-based platform and our lead development candidate, NMT.001. We are thrilled to have the support of leading international investors, who share our vision of addressing the unmet needs of patients living with neurological disorders. This funding is essential to bring NMT.001 to clinical trials and advance our pipeline.”

Angelini Ventures’ investment in Neumirna represents its 5th investment in the field of neurological disorders, supporting a critical therapeutic area with high growth potential.